Regenicin, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGIN research report →
About the company
Regenicin, Inc. is dedicated to the development and commercialization of advanced tissue-engineered skin replacement technologies. Its product line features NovaDerm, a sophisticated multi-layered living and cultured skin substitute engineered for treating burn injuries, alongside TempaDerm, which addresses more localized wound areas like ulcers.
- CEO
- Randall E. McCoy
- IPO
- 2009
- Employees
- 3
- HQ
- Little Falls, NJ, US
Price Chart
- Market Cap
- $15.35K
- P/E
- -0.02
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 11.88%
- ROIC
- 12.13%
- Revenue
- $0 · 0.00%
- Net Income
- $-639,000 · 4.71%
- EPS
- $-0.00 · 6.25%
- Op Income
- $-601,000
- FCF YoY
- -13.21%
- 52W High
- $0.75
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -2.27
- Avg Volume
- 60.41K
Get TickerSpark's AI analysis on RGIN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RGIN coverage
Recent articles, reports, and earnings notes.
No research on RGIN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGIN report →Similar companies
Peers in the same neighborhood.